Loading stock data…
Clene Inc (CLNN)
$3.62-0.23 (-5.97%)
Market ClosedLast close Sep 8
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Clene Inc. in the Consumer Defensive sector is trading at $3.62 with a market capitalization of $71M. Wall Street consensus targets $32.20 (5 analysts), implying a +789.5% move over the next 12 months. The stock is currently near its 52-week low of $3.60, remaining 37.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +789.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15,000↓ | $77,000↑ | $15,000↓ | $27,000↓ | $81,000 |
| Gross Profit | $15,000↓ | $54,000↑ | $15,000↓ | $27,000↓ | $61,000 |
| Operating Income | -$1.69M↑ | -$7.24M↓ | -$5.37M↑ | -$5.63M↓ | -$3.57M |
| Net Income | -$8.09M↑ | -$9.23M↓ | -$8.78M↓ | -$7.42M↓ | -$751,000 |
Peer Comparison
Fundamentals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in vario...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$70.79M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
178.20%
Volume
Today's trading volume
252,477
Recent News
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Etherington said the co
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.